Bologna C, Poirier J L, Hérisson C, Simon L
Service de Rhumatologie, Hôpital Lapeyronie, Montpellier.
Rev Rhum Mal Osteoartic. 1991 Oct;58(9):595-9.
The occurrence of ossifying enthesopathy during treatment with synthetic retinoids (etretinate, isotretinoin and acitretin) is a side-effect more and more frequently recorded. The authors report here a new case in a patient with a severe psoriatic arthritis. This observation is characterized by the size of ossifications on hips and lumbar spine which appeared after two years of etretinate therapy. The interest of this observation lies in the fact that ossifications occurred while the patient was treated with long-term corticotherapy. The disease for which retinoids are prescribed does not seem to influence the occurrence of those lesions and it is likely that the responsibility of these molecules is entire. Lesions are enthesitis ossification. They are frequent during these treatments (average of 70%) after an average time of 24 to 36 months for etretinate and of 10 months for isotretinoin. Lesions are asymptomatic in about 50% of the cases. After discontinuation of treatment, lesions become quiescent and does not disappear. Growth hormone or abnormalities in vitamin A metabolism could play a role in the physiopathology of lesions.
在使用合成维甲酸(依曲替酯、异维A酸和阿维A)治疗期间发生骨化性附着点病是一种越来越常被记录到的副作用。作者在此报告了一名重度银屑病关节炎患者的新病例。该病例的特点是在依曲替酯治疗两年后,髋部和腰椎出现了骨化灶。该病例的意义在于,骨化发生在患者接受长期皮质激素治疗期间。开具维甲酸所针对的疾病似乎并不影响这些病变的发生,这些分子很可能是完全有责任的。病变为骨化性附着点炎。在这些治疗期间很常见(依曲替酯平均为70%),依曲替酯平均24至36个月,异维A酸平均10个月后出现。约50%的病例中病变无症状。停药后,病变静止但不会消失。生长激素或维生素A代谢异常可能在病变的病理生理过程中起作用。